Dose-ranging study of tesetaxel, a novel oral taxane, administered as second-line therapy at a flat dose to patients with advanced gastric cancer.
J. S. Baker
No relevant relationships to disclose
A. Qureshi
Employment or Leadership Position - Genta
Stock Ownership - Genta
L. Itri
Employment or Leadership Position - Genta (B)
Stock Ownership - Genta (B)
W. Sun
Research Funding - Genta
M. F. Mulcahy
No relevant relationships to disclose
J. A. Ajani
No relevant relationships to disclose